Hydrocodone

Hydrocodone, also known as dihydrocodeinone, is a semisynthetic opioid used to treat pain and as a cough suppressant. It is taken by mouth.

Hydrocodone
Clinical data
Trade namesHysingla ER, Zohydro ER
Other namesDihydrocodeinone, hydrocodone bitartrate
AHFS/Drugs.comMonograph
MedlinePlusa601006
License data
Dependence
liability		High
Addiction
liability		High
Routes of
administration		Clinical: by mouth
Others: intranasal, rectal
Drug classOpioid
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityBy mouth: 70%
Protein bindingLow
MetabolismLiver: CYP3A4 (major), CYP2D6 (minor)
Metabolites• Norhydrocodone
• Hydromorphone
• Others
Onset of action10–20 minutes
Elimination half-lifeAverage: 3.8 hours
Range: 3.3–4.4 hours
Duration of action4–8 hours
ExcretionUrine
Identifiers
  • 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.004.304 Edit this at Wikidata
  (verify)

Most of the time it is dispensed as the combination acetaminophen/hydrocodone or ibuprofen/hydrocodone for pain severe enough to require an opioid and in combination with homatropine methylbromide to relieve cough. It is also available by itself in a long-acting form under the brand name Zohydro ER, among others, to treat long-term severe pain.

References

  1. 1 2 3 4 "Hydrocodone Bitartrate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 April 2019.
  2. ↑ Bonewit-West K, Hunt SA, Applegate E (2012). Today's Medical Assistant: Clinical and Administrative Procedures. Elsevier Health Sciences. p. 571. ISBN 9781455701506.
  3. 1 2 3 4 Elliott JA (19 April 2016). "Opioids in the management of acute pain". In Elliott JA, Smith HS (eds.). Handbook of Acute Pain Management. CRC Press. pp. 79–. ISBN 978-1-4665-9635-1.
  4. ↑ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  5. 1 2 Polsten GR, Wallace MS (21 June 2016). "Analgesic Agents in Rheumatic Disease". In Firestein GS, Budd R, Gabriel SE, McInnes IB, O'Dell JR (eds.). Kelley and Firestein's Textbook of Rheumatology. Elsevier Health Sciences. pp. 1081–. ISBN 978-0-323-41494-4.
  6. ↑ Chabner BA, Longo DL (8 November 2010). "Chapter 37: Drug Therapy of Pain in Cancer Patients". Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 700–. ISBN 978-1-60547-431-1.
  7. 1 2 3 4 Zhou S (6 April 2016). "Substrates of Human CYP2D6: Opioids and Opioid Receptor Antagonists". Cytochrome P450 2D6: Structure, Function, Regulation and Polymorphism. CRC Press. pp. 164–. ISBN 978-1-4665-9788-4.
  8. ↑ Davis MP, Glare P, Hardy J (2005). Opioids in Cancer Pain. Oxford University Press. pp. 59–68. ISBN 978-0-19-852943-9.
  9. ↑ Bluth MH (16 November 2016). Toxicology and Drug Testing, An Issue of Clinics in Laboratory Medicine, E-Book. Elsevier Health Sciences. pp. 85–. ISBN 978-0-323-47795-6.
  10. ↑ Smith HS (21 February 2013). Opioid Therapy in the 21st Century. OUP USA. pp. 68–. ISBN 978-0-19-984497-5.
  11. ↑ Mallinckrodt (March 10, 2021). "HYDROCODONE BITARTRATE AND ACETAMINOPHEN tablet (label)". National Institutes of Health DailyMed. Retrieved November 6, 2021.
  12. ↑ Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams & Wilkins. p. 692. ISBN 9781608317080.
  13. ↑ "Hydrocodone Combination Products: MedlinePlus Drug Information". medlineplus.gov. Retrieved 2023-11-04.
  14. ↑ "Hydrocodone: MedlinePlus Drug Information". medlineplus.gov. Retrieved 15 April 2019.